Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Result of AGM

30th Jun 2025 14:15

RNS Number : 0274P
N4 Pharma PLC
30 June 2025
 

 

30 June 2025

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

Result of AGM

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. 

Resolution

For

For%

Against

Against%

Total

Witheld votes*

Ordinary Resolution 1

To receive the annual report and audited accounts for the year

ended 31 December 2024

30,108,642

99.98%

7,304

0.02%

30,115,946

300,591

Ordinary Resolution 2

To re-elect Luke Cairns as a Director of the Company

30,061,328

99.98%

7,304

0.02%

30,068,632

98,809

Ordinary Resolution 3

To re-elect Chris Britten as a Director of the Company

30,061,328

99.98%

7,304

0.02%

30,068,632

98,809

Ordinary Resolution 4

To elect Michael Palfreyman as a Director of the Company

30,085,134

99.97%

8,504

0.03%

30,093,638

80,791

Ordinary Resolution 5

To elect Alastair Smith as a Director of the Company

30,078,746

99.97%

8,504

0.03%

30,087,250

80,791

Ordinary Resolution 6

To appoint Gravita Audit II Limited as the Companyʼs auditor

and to authorise the Directors to determine their remuneration

30,085,034

99.98%

7,304

0.02%

30,092,338

93,799

Ordinary Resolution 7

To authorise the Directors to allot shares

 

 

 

30,060,137

 

 

 

99.98%

 

 

 

7,304

 

 

 

0.02%

 

 

 

30,067,441

 

 

 

92,193

Special Resolution 8

To disapply pre-emption rights

29,942,019

99.97%

10,004

0.03%

29,952,023

92,393

 

*Please note a vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

 

- Ends -

 

For more information please contact:

 

N4 Pharma plc

Nigel Theobald, CEO

Luke Cairns, Executive Director

 

Submit your questions directly to the management team via the N4 Pharma Investor Hub

 

 

Via N4 Pharma Investor Hub: investors.n4pharma.com

 

https://investors.n4pharma.com/link/5PmqMP

SP Angel Corporate Finance LLP

Nominated Adviser and Joint Broker

Matthew Johnson/Jen Clarke (Corporate Finance)

Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Tel: +44 (0)20 3470 0470

Turner Pope Investments (TPI) Limited

Joint Broker

Andy Thacker

James Pope

Tel: +44 (0)20 3657 0050

Northstar Communications Limited

Investor Relations

Sarah Hollins

Tel: +44 (0)113 730 3896

 

 

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

 

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

 

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

 

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.

 

For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGBXGDLSBXDGUG

Related Shares:

N4 Pharma Plc
FTSE 100 Latest
Value8,740.18
Change-20.78